Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day

Core Insights - Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD) to develop innovative small molecule medicines [2][1] - The company will participate in a fireside chat at the UBS Virtual TPD Day on July 15, 2024, at 1:00 p.m. ET, with a live webcast available on its website [1] Company Overview - Kymera Therapeutics is pioneering TPD to address critical health issues and improve patient outcomes, having advanced the first degrader into clinical trials for immunological diseases [2] - The company aims to deliver oral small molecule degraders as a new generation of effective therapies for patients, while also developing oncology programs targeting undrugged or poorly drugged proteins [2] - Founded in 2016, Kymera has been recognized as one of Boston's top workplaces in recent years [2]